Leveraging Programmatic Collaboration for a Radiopharmaceutical Clinic
Radiation oncologists, radiopharmacists, nuclear medicine physicians, and medical oncologists have seen a renewed clinical interest in radiopharmaceuticals for the curative or the palliative treatment of cancer. To allow for the discovery and the clinical advancement of targeted radiopharmaceuticals...
Main Authors: | Charles A. Kunos, Molly E. Martin, Michalis F. Georgiou, Russ A. Kuker, Aman Chauhan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/16/7/1396 |
Similar Items
-
Beyond Small Molecules: Antibodies and Peptides for Fibroblast Activation Protein Targeting Radiopharmaceuticals
by: Xiaona Sun, et al.
Published: (2024-02-01) -
The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker
by: Holis Abdul Holik, et al.
Published: (2022-05-01) -
Current Status and Future Prospects of Theranostics with Radiopharmaceuticals
by: LUO Yaping, et al.
Published: (2023-07-01) -
Regulation of Radiopharmaceutical Products
by: V. V. Kosenko, et al.
Published: (2022-12-01) -
Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy
by: Liesbeth Everix, et al.
Published: (2023-02-01)